One-year clinical outcome with a novel self-expanding transcatheter heart valve.

Costanza Pellegrini Tobias RheudeTeresa TrenkwalderNicola Patrick MayrJonathan MichelAdnan KastratiHeribert SchunkertAlbert M KaselMichael JonerChristian HengstenbergOliver Husser

Published in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2019)

Using the ACURATE neo, we found a favorable safety profile with low all-cause mortality at 1 year. The reported VARC-2 defined composite endpoints at 1 year reveal low rates of "clinical efficacy after 30 days" and "time-related valve safety".

Keyphrases

aortic valve
mitral valve
aortic stenosis
heart failure
transcatheter aortic valve replacement
genome wide
atrial fibrillation
single cell
gene expression
ejection fraction
coronary artery disease